New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies

References

• Agawa T, Usui Y, Wakabayashi Y, et al. (2014). Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection. Retina J Ret Vit Dis 34:1811–8.
   PubMed Web of Science ®Google Scholar
• Agrawal RN, He S, Spee C, et al. (2007). In vivo models of proliferative vitreoretinopathy. Nat Protoc 2:67–77.
   PubMed Web of Science ®Google Scholar
• Arimura S, Takamura Y, Miyake S, et al. (2016). The effect of triamcinolone acetonide or bevacizumab on the levels of proinflammatory cytokines after retinal laser photocoagulation in pigmented rabbits. Exp Eye Res 149:1–7.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Omar AF, Iezzi R, Kapoor KG. (2016). Evaluation of multiple dexamethasone intravitreal implants in patients with macular edema associated with retinal vein occlusion. Retina J Ret Vit Dis 36:552–7.
   PubMed Web of Science ®Google Scholar
• Banerjee PJ, Quartilho A, Bunce C, et al. (2017). Slow-release dexamethasone in proliferative vitreoretinopathy. Ophthalmology 124:757–67.
   PubMed Web of Science ®Google Scholar
• Bochaton-Piallat ML, Kapetanios AD, Donati G, et al. (2000). TGF-beta 1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci 41:2336–42.
   PubMed Web of Science ®Google Scholar
• Browning AC, Chung AK, Ghanchi F, et al. (2005). Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series. Ophthalmology 112:1227–31.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA. (2000). Retinal and choroidal neovascularization. J Cell Physiol 184:301–10.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Mir TA, et al. (2016). Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial. Am J Ophthalmol 168:13–23.
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. (2011). Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52:80–6.
   PubMed Web of Science ®Google Scholar
• Cheng L, Anglin E, Cunin F, et al. (2008). Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle. Br J Ophthalmol 92:705–11.
   PubMed Web of Science ®Google Scholar
• Cheng LY, Hostetler K, Valiaeva N, et al. (2010). Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest Ophthalmol Vis Sci 51:474–81.
   PubMed Web of Science ®Google Scholar
• El Bradey M, Cheng LY, Bartsch DU, et al. (2004). Preventive versus treatment effect of Ag3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization. J Ocul Pharmacol Ther 20:217–36.
   PubMed Web of Science ®Google Scholar
• El-Ghrably IA, Saad A, Dinah C. (2015). A novel technique for repositioning of a migrated ILUVIEN((R)) (Fluocinolone Acetonide) implant into the anterior chamber. Ophthalmol Ther 4:129–33.
   PubMed Web of Science ®Google Scholar
• Frank RN, Das A, Weber ML. (1989). A model of subretinal neovascularization in the pigmented rat. Curr Eye Res 8:239–47.
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Kang SJ, Berglin L. (2010). Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 29:500–19.
   PubMed Web of Science ®Google Scholar
• Heier JS, Bressler NM, Avery RL, et al. (2016). Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema extrapolation of data to clinical practice. Jama Ophthalmol 134:95–9.
   PubMed Web of Science ®Google Scholar
• Hou H, Huffman K, Rios S, et al. (2015). A novel approach of daunorubicin application on formation of proliferative retinopathy using a porous silicon controlled delivery system: pharmacodynamics. Invest Ophthalmol Vis Sci 56:2755–63.
   PubMed Web of Science ®Google Scholar
• Hou H, Nieto A, Ma F, et al. (2014). Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon. J Control Release 178:46–54.
   PubMed Web of Science ®Google Scholar
• Hou HY, Wang CY, Nan KH, et al. (2016). Controlled release of dexamethasone from an intravitreal delivery system using porous silicon dioxide. Invest Ophthalmol Vis Sci 57:557–66.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Miller H, Orr G, et al. (1987). Morphological observations on experimental subretinal neovascularization in the monkey. Invest Ophthalmol Vis Sci 28:1116–30.
   PubMed Web of Science ®Google Scholar
• Ishida K, Yoshimura N, Mandai M, Honda Y. (1999). Inhibitory effect of TNP-470 on experimental choroidal neovascularization in a rat model. Invest Ophthalmol Vis Sci 40:1512–9.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, Nomenclatu SU. (2005). Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509–16.
   PubMed Web of Science ®Google Scholar
• Jaffuel D, Roumestan C, Balaguer P, et al. (2001). Correlation between different gene expression assays designed to measure trans-activation potencies of systemic glucocorticoids. Steroids 66:597–604.
   PubMed Web of Science ®Google Scholar
• Kimura H, Sakamoto T, Hinton DR, et al. (1995). A new model of subretinal neovascularization in the rabbit. Invest Ophthalmol Vis Sci 36:2110–9.
   PubMed Web of Science ®Google Scholar
• Liu F, Ding XY, Yang Y, et al. (2016). Aqueous humor cytokine profiling in patients with wet AMD. Mol Vis 22:352–61.
   PubMed Web of Science ®Google Scholar
• Madow B, Galor A, Feuer WJ, et al. (2011). Validation of a photographic vitreous haze grading technique for clinical trials in uveitis. Am J Ophthalmol 152:170–6.
   PubMed Web of Science ®Google Scholar
• Meyer LM, Schonfeld CL. (2013). Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up. J Ocul Pharmacol Ther 29:560–5.
   PubMed Web of Science ®Google Scholar
• Mietz H, Heimann K. (1995). Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal diseases. Br J Ophthalmol 79:874–7.
   PubMed Web of Science ®Google Scholar
• Ni M, Holland M, Jarstadmarken H, De Vries G. (2005). Time-course of experimental choroidal neovascularization in Dutch-Belted rabbit: clinical and histological evaluation. Exp Eye Res 81:286–97.
   PubMed Web of Science ®Google Scholar
• Nieto A, Hou H, Sailor MJ, et al. (2013). Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles. Exp Eye Res 116:161–8.
   PubMed Web of Science ®Google Scholar
• Pardo-Lopez D, Frances-Munoz E, Gallego-Pinazo R, Diaz-Llopis M. (2012). Anterior chamber migration of dexametasone intravitreal implant (Ozurdex(R)). Graefes Arch Clin Exp Ophthalmol 250:1703–4.
   PubMed Web of Science ®Google Scholar
• Pena RA, Jerdan JA, Glaser BM. (1994). Effects of TGF-beta and TGF-beta neutralizing antibodies on fibroblast-induced collagen gel contraction: implications for proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 35:2804–8.
   PubMed Web of Science ®Google Scholar
• Qiu G, Stewart JM, Sadda S, et al. (2006). A new model of experimental subretinal neovascularization in the rabbit. Exp Eye Res 83:141–52.
   PubMed Web of Science ®Google Scholar
• Ramu J, Yang Y, Menon G, et al. (2015). A randomized clinical trial comparing fixed vs. pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study). Eye 29:1603–12.
   PubMed Web of Science ®Google Scholar
• Rezar-Dreindl S, Sacu S, Eibenberger K, et al. (2016). The intraocular cytokine profile and therapeutic response in persistent neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 57:4144–50.
   PubMed Web of Science ®Google Scholar
• Sha O, Kwong WH. (2006–07). Postnatal developmental changes of vitreous and lens volumes in sprague–dawley rats. Neuroembryol Aging 4:183–8.
   Google Scholar
• Teoh SC, Ou XL, Lim TH. (2012). Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen. Ophthalmology 119:588–95.
   PubMed Web of Science ®Google Scholar
• Wang C, Hou H, Nan K, et al. (2014a). Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide. Exp Eye Res 129:74–82.
   PubMed Web of Science ®Google Scholar
• Wang CY, Hou HY, Nan KH, et al. (2014b). Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide. Exp Eye Res 129:74–82.
   PubMed Web of Science ®Google Scholar
• Wang JK, Huang TL, Su PY, Chang PY. (2015). An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema. Eye Sci 30:176–83.
   PubMedGoogle Scholar
• Wells JA, Glassman AR, Ayala AR, et al. (2015). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193–203.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. (2016a). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:1351–9.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Jampol LM. (2016b). Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema (vol 134, pg 127, 2016). JAMA Ophthalmol 134:469.
   Web of Science ®Google Scholar
• Xu Y, Tan CS. (2017). Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol 37:325–332.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kobayashi Y, Nakao S, et al. (2017). Differential association of elevated inflammatory cytokines with postoperative fibrous proliferation and neovascularization after unsuccessful vitrectomy in eyes with proliferative diabetic retinopathy. Opth 11:1697–1705.
   Web of Science ®Google Scholar